Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
1982 1
1985 2
1986 1
1987 1
1988 1
1989 1
1992 1
1994 1
1995 2
1996 3
1999 1
2000 1
2006 3
2007 1
2008 2
2009 2
2011 3
2012 2
2013 2
2015 2
2016 2
2017 3
2018 1
2019 1
2020 1
2022 1
2024 2
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Hypertonic Saline or Carbocisteine in Bronchiectasis.
Bradley JM, O'Neill B, McAuley DF, Chalmers JD, De Soyza A, Hill AT, Carroll M, Loebinger MR, Duckers J, Clarke M, McLeese RH, Ferguson K, Jackson A, Campbell C, McDowell C, Agus A, Norrie J, Copeland F, Downey DG, Convery R, Kelly M, Flight W, Talbot NP, Hurst JR, Steer J, Anwar M, Shahidi M, Gatheral T, Etumi M, Sullivan AL, Ionescu AA, Patil V, Bhattacharya M, Caskey S, Cosgrove D, Hagan C, Shoemark A, McManus T, Davies G, Elborn JS; CLEAR Investigator Team. Bradley JM, et al. N Engl J Med. 2025 Oct 23;393(16):1565-1577. doi: 10.1056/NEJMoa2510095. Epub 2025 Sep 28. N Engl J Med. 2025. PMID: 41020514 Clinical Trial.
All participants received standard care and were also assigned either to one of three mucoactive-drug groups - hypertonic saline (the hypertonic-saline group), hypertonic saline and carbocisteine (the combination group), or carbocisteine (the carbocisteine gr …
All participants received standard care and were also assigned either to one of three mucoactive-drug groups - hypertonic saline (the hypert …
Efficacy of Carbocisteine in Reducing Exacerbations in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kow CS, Hasan SS, Thiruchelvam K. Kow CS, et al. Adv Respir Med. 2025 Dec 31;94(1):2. doi: 10.3390/arm94010002. Adv Respir Med. 2025. PMID: 41562960 Free PMC article.
Mechanistically, carbocisteine improves mucociliary clearance, suppresses airway inflammation, reduces oxidative stress, and may hinder bacterial colonization. Carbocisteine is associated with a significant reduction in COPD exacerbations and demonstrates a favorabl …
Mechanistically, carbocisteine improves mucociliary clearance, suppresses airway inflammation, reduces oxidative stress, and may hind …
Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.
Zeng Z, Yang D, Huang X, Xiao Z. Zeng Z, et al. Int J Chron Obstruct Pulmon Dis. 2017 Aug 2;12:2277-2283. doi: 10.2147/COPD.S140603. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28814855 Free PMC article.
There was a decrease in the risk of the rate of total number of exacerbations with carbocisteine compared with placebo (-0.43; 95% confidence interval [CI] -0.57, -0.29, P<0.01). Carbocisteine could also improve the quality of life (-6.29; 95% CI -9.30, -3.27) an …
There was a decrease in the risk of the rate of total number of exacerbations with carbocisteine compared with placebo (-0.43; 95% co …
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Ohnishi H, et al. Respir Investig. 2024 Nov;62(6):1168-1175. doi: 10.1016/j.resinv.2024.10.004. Epub 2024 Oct 15. Respir Investig. 2024. PMID: 39413571
METHODS: Reports from randomized controlled trials to evaluate the efficacy and safety of mucolytics, including ambroxol, bromhexine, carbocisteine, erdosteine, fudosteine, l-methylcysteine, and N-acetylcysteine used in patients with stable COPD were searched for in PubMed …
METHODS: Reports from randomized controlled trials to evaluate the efficacy and safety of mucolytics, including ambroxol, bromhexine, car …
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Rogliani P, et al. Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y. Respir Res. 2019. PMID: 31133026 Free PMC article.

The network meta-analysis provided the following rank of effectiveness: erdosteine>carbocysteine>NAC. Only erdosteine reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05). ...CONCLUSIONS: The o

…
The network meta-analysis provided the following rank of effectiveness: erdosteine>carbocysteine>NAC. Only erdosteine reduced t …
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS. Zheng JP, et al. Lancet. 2008 Jun 14;371(9629):2013-8. doi: 10.1016/S0140-6736(08)60869-7. Lancet. 2008. PMID: 18555912 Clinical Trial.
FINDINGS: 354 patients were assigned to the carbocisteine group and 355 to the placebo group. Numbers of exacerbations per patient per year declined significantly in the carbocisteine group compared with the placebo group (1.01 [SE 0.06] vs 1.35 [SE 0.06]), risk rat …
FINDINGS: 354 patients were assigned to the carbocisteine group and 355 to the placebo group. Numbers of exacerbations per patient pe …
Effect of Carbocysteine on Exacerbations and Lung Function in Patients With Mild-to-Moderate Chronic Obstructive Pulmonary Disease: A Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial.
Zhou Y, Wu F, Li H, Deng Z, Lin L, Huang H, Zhao H, Wang Y, Wang L, Cheng Q, Cai S, He Z, Ying Y, Huang P, Tian H, Peng J, Xiao S, Wen X, Yang H, Zhen Y, Wang Z, Zhao N, Lu L, Xu J, Wang Q, Ran P; China Carbocysteine in Mild-to-moderate COPD Study Group. Zhou Y, et al. Arch Bronconeumol. 2025 Sep;61(9):528-535. doi: 10.1016/j.arbres.2025.01.004. Epub 2025 Jan 6. Arch Bronconeumol. 2025. PMID: 40000348 Clinical Trial. English, Spanish.
The objective of the study was to evaluate the efficacy of carbocysteine on the rate of exacerbations and pulmonary function for mild-to-moderate COPD patients. ...Among 539 patients, 362 were randomized to receive carbocysteine and 177 to receive matched placebo. T …
The objective of the study was to evaluate the efficacy of carbocysteine on the rate of exacerbations and pulmonary function for mild …
Efficacy of combined treatment with S-carboxymethylcysteine (carbocisteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp.
Majima Y, Kurono Y, Hirakawa K, Ichimura K, Haruna S, Suzaki H, Kawauchi H, Takeuchi K, Naito K, Kase Y, Harada T, Moriyama H. Majima Y, et al. Auris Nasus Larynx. 2012 Feb;39(1):38-47. doi: 10.1016/j.anl.2011.04.015. Epub 2011 Jun 1. Auris Nasus Larynx. 2012. PMID: 21636230 Clinical Trial.
OBJECTIVE: In Japan, fourteen-membered ring macrolides, antibacterial agents, and S-carboxymethylcysteine (SCMC; carbocisteine), a mucolytic, are commonly used to treat chronic rhinosinusitis (CRS), and they are also used in combination. ...
OBJECTIVE: In Japan, fourteen-membered ring macrolides, antibacterial agents, and S-carboxymethylcysteine (SCMC; carbocisteine), a mu …
47 results